EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia

Hanny Al-Samkari iD, Raj S Kasthuri iD, Vivek N Iyer, Allyson M Pishko, Jake E Decker, Clifford R Weiss iD, Kevin J Whitehead, Miles B Conrad, Marc S Zumberg, Jenny Y Zhou, Joseph Parambil, Derek Marsh und 6 weitere

New England Journal of Medicine · 19.09.2024 · 391 (11) · 1015-1027

DOI: 10.1056/nejmoa2312749 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 19.09.2024. Verfasst von Hanny Al-Samkari und 17 weiteren Autor:innen. Beteiligte Einrichtung: From Massachusetts General Hospital, Boston (H.A.-S.); University of North Carolina, Chapel Hill (R.S.K.), and RTI International, Research Triangle P…. Hauptthemen laut MEDLINE: Epistaxis, Telangiectasia, Hereditary Hemorrhagic, Thalidomide. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpistaxisTelangiectasia, Hereditary HemorrhagicThalidomideAgedFemaleHumansMaleMiddle AgedAngiogenesis InhibitorsDouble-Blind MethodQuality of LifeSeverity of Illness IndexTreatment OutcomeNeutropeniaConstipationDrug Eruptions

Substanzen

Angiogenesis InhibitorspomalidomideThalidomide

Autor:innen und Institutionen

  • From Massachusetts General Hospital, Boston (H.A.-S.); University of North Carolina, Chapel Hill (R.S.K.), and RTI International, Research Triangle Park (D.M., L.B., B.A.C., S.M.T.) - both in North Carolina; Mayo Clinic…

ORCID-Profile: Hanny Al-Samkari, Raj S Kasthuri, Clifford R Weiss, Keith R McCrae

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Al-Samkari, H., Kasthuri, R. S., Iyer, V. N., Pishko, A. M., Decker, J. E., Weiss, C. R., Whitehead, K. J., Conrad, M. B., Zumberg, M. S., Zhou, J. Y., Parambil, J., Marsh, D., Clancy, M., Bradley, L., Wisniewski, L., Carper, B. A., Thomas, S. M., & McCrae, K. R. (2024). Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia. New England Journal of Medicine, 391(11), 1015-1027. https://doi.org/10.1056/nejmoa2312749

Vancouver

Al-Samkari H, Kasthuri RS, Iyer VN, Pishko AM, Decker JE, Weiss CR, et al. Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia. New England Journal of Medicine. 2024;391(11):1015-1027. doi:10.1056/nejmoa2312749

BibTeX
@article{AlSamkari2024,
  author = {Al-Samkari, Hanny and Kasthuri, Raj S and Iyer, Vivek N and Pishko, Allyson M and Decker, Jake E and Weiss, Clifford R and Whitehead, Kevin J and Conrad, Miles B and Zumberg, Marc S and Zhou, Jenny Y and Parambil, Joseph and Marsh, Derek and Clancy, Marianne and Bradley, Lauren and Wisniewski, Lisa and Carper, Benjamin A and Thomas, Sonia M and McCrae, Keith R},
  title = {Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {11},
  pages = {1015--1027},
  doi = {10.1056/nejmoa2312749}
}
Kostenlos starten →